Biocon Email Format
Biotechnology ResearchKarnataka, India10001+ Employees
Biocon Limited is an India-based biotechnology research company headquartered in Electronics City, Karnataka. Publicly listed since 2004, it operates as a fully integrated, innovation-led biopharmaceutical firm serving customers in more than 120 countries. Its portfolio blends fermentation-derived small‑molecule APIs with a broad biosimilars pipeline and a growing set of novel biologics in development, aimed at chronic diseases where access to therapy is limited. The company has achieved regulatory milestones for its biosimilars, including insulin products and Trastuzumab-based therapies such as Ogivri, co-developed with Mylan, which is approved in the US. It also leverages its subsidiary Syngene to provide discovery and development services across the life sciences sector and pursues a pipeline of patented biologics to address unmet medical needs. In March 2026 Biocon announced the appointment of Shreehas Tambe as Chief Executive Officer and Managing Director, effective April 1, 2026.